Skip to content

Study · Randomized controlled trial · n = 305 · 2009

3 results

Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).

Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Gomes JM, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Glüer CC

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Apr 2009Cited by 120 (Europe PMC)

PMID19049337 (opens in a new tab)DOI10.1359/jbmr.081215 (opens in a new tab)PepBankPUB-19049337
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with severe osteoporosis, continued teriparatide increased spine BMD by 10.7% from baseline over 2 years.

    In plain wordsIn women with severe osteoporosis, continued teriparatide increased spine bone density from baseline over 2 years.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSpine BMD
    Study

    n = 305

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 2 yearsAs given in this study (human).

    Measurements

    Spine BMD change from baseline
    10.7%
    continued teriparatide, 2 years

    Source sentences

    Summary
    Daily teriparatide treatment for 2 yr significantly increased spine BMD by 10.7%.
    2 context sentences
    Summary · context
    Postmenopausal women with osteoporosis and a recent fragility fracture received open-label teriparatide (20 microg/d) for 12 mo before they were randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg/d (n = 100), or receive no active treatment for the second year (n = 102).
    Summary · context
    All patients received calcium and vitamin D supplementation.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with severe osteoporosis, continued teriparatide increased total hip BMD by 2.5% from baseline at 2 years.

    In plain wordsIn women with severe osteoporosis, continued teriparatide increased total hip bone density from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD
    Study

    n = 305

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 2 yearsAs given in this study (human).

    Measurements

    Total hip BMD change from baseline
    2.5%
    teriparatide, 2 years

    Source sentences

    Summary
    At the total hip, BMD increases from baseline at 2 yr were 2.5% with teriparatide, 2.3% with raloxifene, and 0.5% with no active treatment; the respective changes at the femoral neck were 3.5%, 3.1%, and 1.3%.
    2 context sentences
    Summary · context
    Postmenopausal women with osteoporosis and a recent fragility fracture received open-label teriparatide (20 microg/d) for 12 mo before they were randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg/d (n = 100), or receive no active treatment for the second year (n = 102).
    Summary · context
    All patients received calcium and vitamin D supplementation.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with severe osteoporosis, continued teriparatide increased femoral neck BMD by 3.5% from baseline at 2 years.

    In plain wordsIn women with severe osteoporosis, continued teriparatide increased femoral neck bone density from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n = 305

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 microg/d · 2 yearsAs given in this study (human).

    Measurements

    Femoral neck BMD change from baseline
    3.5%
    teriparatide, 2 years

    Source sentences

    Summary
    At the total hip, BMD increases from baseline at 2 yr were 2.5% with teriparatide, 2.3% with raloxifene, and 0.5% with no active treatment; the respective changes at the femoral neck were 3.5%, 3.1%, and 1.3%.
    2 context sentences
    Summary · context
    Postmenopausal women with osteoporosis and a recent fragility fracture received open-label teriparatide (20 microg/d) for 12 mo before they were randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg/d (n = 100), or receive no active treatment for the second year (n = 102).
    Summary · context
    All patients received calcium and vitamin D supplementation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.